文献速递乳腺癌支持与姑息治疗

日本乳腺癌登记库:老年II/III期乳腺癌全身治疗与预后分析

Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry.
PubMed 文献 · Eur J Cancer · 2021-07-19

该回顾性队列研究基于日本乳腺癌登记库2004–2011年数据,纳入56093例≥55岁II/III期原发性乳腺癌患者,比较≥75岁老年组与年轻组的治疗和预后。老年组化疗使用率在luminal型为9.2%、三阴性为32.9%、HER2阳性为27.4%;三阴性和HER2阳性老年组乳腺癌特异性生存(BCSS)较差,但匹配后化疗与luminal和HER2阳性亚型总生存(OS)改善相关。

要点

  • 老年组化疗使用率低:luminal型仅9.2%,三阴性32.9%,HER2阳性27.4%。
  • 三阴性和HER2阳性老年患者BCSS较年轻患者差,所有亚型OS均较差。
  • 匹配后化疗与luminal和HER2阳性老年患者OS改善相关。

核心结论

  • 老年II/III期乳腺癌患者化疗使用率较低,三阴性和HER2阳性者BCSS较年轻患者差。
  • 匹配分析显示化疗可能改善luminal和HER2阳性老年患者的总生存。
  • 老年患者治疗应基于肿瘤因素、生活质量和健康状况个体化制定。

研究设计与样本

  • 回顾性队列研究,基于日本乳腺癌登记库2004–2011年数据。
  • 纳入56093例≥55岁II/III期原发性乳腺癌患者,其中≥75岁12727例、65–74岁17860例、55–64岁25506例。

主要发现

  • 老年组化疗使用率:luminal型9.2%,三阴性32.9%,HER2阳性27.4%。
  • luminal型各年龄组5年BCSS均约95%,三阴性和HER2阳性老年组BCSS较差。
  • 所有亚型中老年组5年OS均较差。
  • 经临床病理因素匹配后,老年患者化疗与luminal和HER2阳性亚型OS改善相关。

临床怎么用

  • 对老年II/III期乳腺癌患者,应结合肿瘤亚型、生活质量和健康状况个体化决策全身治疗。
  • 三阴性和HER2阳性老年患者预后较差,需关注治疗强度与支持治疗。
  • luminal和HER2阳性老年患者可考虑化疗以改善总生存。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • 数据来源于登记库,化疗方案和剂量等细节未报告。
  • 仅纳入日本患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: This study aimed at investigating the real-world prognostic impact of systemic treatment in older patients with stage II/III breast cancer (BC). METHODS: This retrospective cohort study included patients with stage II/III primary BC, aged ≥55 years, and registered in the Japanese Breast Cancer Registry from 2004 to 2011. The clinicopathological characteristics, treatments, and prognosis of patients aged ≥75 years (older) were compared to those of younger patients. RESULTS: In total, 56,093 patients (12,727, ≥75 years; 17,860, 65-74 years; 25,506, 55-64 years) were enrolled. In the older group, 9.2% with a luminal (hormone receptor [HR]+/human epidermal growth factor receptor 2 [HER2]-), 32.9% with a triple-negative (TN, HR-/HER2-), and 27.4% with a HER2-positive (any-HR/HER2+) receptor were administered chemotherapy. In those with luminal cancer, the 5-year breast cancer-specific survival (BCSS) was approximately 95% in all age groups. Meanwhile, among those with TN and HER2-positive BC, the older group had a poorer BCSS. The 5-year overall survival (OS) was also poorer in the older group across all subtypes. Among older patients matched using clinicopathological factors, chemotherapy use was associated with improved OS in the luminal and HER2-positive subtypes. CONCLUSIONS: Chemotherapy use was lower among older patients with stage II/III breast cancer. Those with TN and HER2-positive BC had a lower BCSS than their younger counterparts. Chemotherapy may be beneficial in improving the OS in older patients with luminal and HER2-positive BCs. Treatment for older patients should be individualized, based on tumor-related factors, quality of life, and the patient's health status.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yamada A, Kumamaru H, Shimizu C, et al. Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry. Eur J Cancer. 2021. PMID: 34293663. doi:10.1016/j.ejca.2021.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。